Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057564 · ClinicalTrials.gov registry record · Phase 3
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
A Phase 3 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 470
- Enrollment target
NCT00057564: Completed Phase 3 study, sponsored by Celgene Corporation.
NCT00057564 is a Phase 3 study that has completed, run by Celgene Corporation. The registered enrollment target is 470 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057564, a Phase 3 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 470 participants
- Enrollment target
Study Summary
To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma
Primary Outcome
Time to tumor progression (TTP)
Interventions
- DRUG A (Thalidomide + Dexamethasone)
- DRUG B (Placebo + Dexamethasone)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2003-02 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
What the finished NCT00057564 record still lists
NCT00057564 is an interventional study that assigns participants to a tested intervention. The registered 470 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 2 interventions - of which A (Thalidomide + Dexamethasone) is the first listed.
NCT00057564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00057564 about?
NCT00057564 is a clinical study titled "A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma". To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma
What is the current status of trial NCT00057564?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 470 participants. The study started on 2003-02. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00057564?
The interventions under investigation include: A (Thalidomide + Dexamethasone) (DRUG), B (Placebo + Dexamethasone) (DRUG).
Who is sponsoring clinical trial NCT00057564?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00057564's enrollment target sits among peer trials
470 813th of 2000 higher than 1,186 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia